Cell therapy trial for hard-to-control one-sided temporal lobe epilepsy
Part of Brain & nervous system clinical trials.
This Phase 3 study tests a neural cell therapy (NRTX-1001) for adults whose seizures come from one side of the hippocampus and have not improved with standard seizure medicines. The goal is to reduce seizure frequency and improve seizure control where other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old
- Your epilepsy involves focal seizures starting on one side of the mesial temporal lobe (hippocampus)
- You’ve tried at least 2 appropriate seizure medicines and still don’t have good control
- Your seizure medicine doses have been stable for at least 1 month
- Imaging tests show your seizure focus is only inside one hippocampus (single-sided)
- You have frequent seizures (Phase 3: at least 2 disabling seizures per 28 days on both past and short pre-treatment monitoring)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
This study tests a type of brain stimulation in people with epilepsy to see if it can help preserve memory. Researchers will compare memory and brain effects over time to understand whether stimulation changes memory outcomes.
This trial tests a new cell therapy (NRTX-1001) for people with epilepsy that starts in both sides of the brain's temporal lobes and doesn't get better with medication. It aims to reduce or stop seizures.
This trial tests a new cell therapy, UX-GIP001, for people whose seizures start in one small area of the brain (the mesial temporal lobe) and are not controlled by at least two seizure medications. The goal is to see if this treatment can safely reduce seizures.
This trial tests a new cell-based treatment for people with epilepsy that has not improved with standard medications. The treatment aims to reduce seizures in patients with a specific type of epilepsy originating from one side of the brain.
This trial tests a brain stimulation treatment for people with temporal lobe epilepsy that doesn't improve with medication. The goal is to see if it can reduce seizures.
Hear when a new Mesial Temporal Lobe Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.